Surgical treatment of arrhythmias is often more expeditious and more cost-effective in the long run than pharmacologic therapy. In the past, surgical treatment of arrhythmias has been reserved for patients with disabling paroxysmal or incessant tachycardia refractory to medical management, severe life-threatening arrhythmia or aborted episodes of sudden death. However, tachyarrhythmias that are refractory to pharmacologic therapy because of drug inefficacy, noncompliance or limiting side effects are not uncommon. Although nonpharmacologic treatment of arrhythmias carries with it a one-time period of higher risk (i.e., when the patient undergoes surgery), it is curative and often preferable to the uncertainty and possibly higher cumulative risk associated with medical management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9149(88)90738-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diuretics for preventing and treating acute kidney injury.
Cochrane Database Syst Rev
January 2025
Department of Psychiatry, Soseikai General Hospital, Kyoto, Japan.
Background: Acute kidney injury (AKI) is a well-known complication of critical illnesses, significantly affecting morbidity and the risk of death. Diuretics are widely used to ameliorate excess fluid accumulation and oliguria associated with AKI. Their popularity stems from their ability to reduce the energy demands of renal tubular cells by inhibiting transporters and flushing out intratubular casts.
View Article and Find Full Text PDFNaxos disease is a rare autosomal recessive condition combining arrhythmogenic right ventricular cardiomyopathy, woolly hair, and palmoplantar keratoderma. The first identified causative variant was in the gene encoding the desmosomal protein plakoglobin. Naxos disease exhibits fibro-fatty myocardial replacement with immunohistological abnormalities in cardiac protein and signaling pathways, highlighting the role of inflammation and potential anti-inflammatory treatments.
View Article and Find Full Text PDFEffects of combo therapy with coenzyme Q10 and mitochondrial transplantation on myocardial ischemia/reperfusion-induced arrhythmias in aged rats.
Iran J Basic Med Sci
January 2025
Molecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Objectives: Ischemia/reperfusion (IR)-induced ventricular arrhythmia, which mainly occurs after the opening of coronary artery occlusion, poses a clinical problem. This study aims to investigate the effectiveness of pretreatment with coenzyme Q (CoQ) in combination with mitochondrial transplantation on IR-induced ventricular arrhythmias in aged rats.
Materials And Methods: Myocardial IR induction was performed by left anterior descending coronary artery occlusion for 30 min, followed by re-opening for 24 hr.
Examining the arrhythmogenicity of dobutamine when used in conjunction with isoflurane in horses: A retrospective study at a single university teaching hospital.
Vet Rec
January 2025
Department of Clinical Sciences, Auburn University, Auburn, Alabama, USA.
Background: Dobutamine is used to treat hypotension in isoflurane-anaesthetised horses but may produce arrhythmias. Halothane is a volatile anaesthetic that was, historically, widely used in horses, but in one study, 56 of 200 halothane-anaesthetised horses (28%) developed arrhythmias after dobutamine administration. Although isoflurane has largely replaced halothane, it is unknown how isoflurane and dobutamine interact in the development of arrhythmias.
View Article and Find Full Text PDFSodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.
BMC Cardiovasc Disord
January 2025
The second Affiliated Hospital of Xi'an Jiaotong University, Xinjiang Hospital (People's Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital), Urumqi, Xinjiang, 830026, People's Republic of China.
Background: Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!